Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Intelence, Etravirine, HIV Infections, Date of Authorisation: 28/08/2008, Revision: 23, Status: Authorised
Case Medical Research
doi 10.31525/cmr-145d59c
Full Text
Open PDF
Abstract
Available in
full text
Date
August 5, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Farydak, Panobinostat, Multiple Myeloma, Date of Authorisation: 28/08/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Pregabalin Accord, Pregabalin, Anxiety Disorders,Epilepsy, Date of Authorisation: 28/08/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Lenvima, Lenvatinib, Thyroid Neoplasms, Date of Authorisation: 28/05/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Odomzo, Sonidegib, Carcinoma, Basal Cell, Date of Authorisation: 14/08/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Palonosetron Hospira, Palonosetron, Nausea,Vomiting,Cancer, Date of Authorisation: 08/04/2016, Revision: 4, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Duloxetine Lilly, Duloxetine, Neuralgia,Diabetic Neuropathies, Date of Authorisation: 08/12/2014, Revision: 4, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Lumigan, Bimatoprost, Glaucoma, Open-Angle,Ocular Hypertension, Date of Authorisation: 08/03/2002, Revision: 30, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Ivabradine Anpharm, Ivabradine, Angina Pectoris,Heart Failure, Date of Authorisation: 08/09/2015, Revision: 4, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Steglujan, Ertugliflozin / Sitagliptin, Diabetes Mellitus, Type 2, Date of Authorisation: 23/03/2018, Revision: 4, Status: Authorised
Case Medical Research
